Biogaia AB (BIOG B.ST) stock: key figures, P/E, revenue and dividend

Health Care · Sweden · ISIN SE0017769995

Price
121.90 SEK
Market cap
12.33 bn SEK
P/E (2025)
37.06
P/S (2025)
8.02
Dividend yield
3.28 %
Net margin
21.59 %
Return on equity (ROE)
25.26 %
Return on assets (ROA)
20.78 %

Biogaia AB financials

Fiscal year20242025
Revenue1.42 bn SEK1.54 bn SEK
Gross profit1.03 bn SEK1.13 bn SEK
Operating income460.51 m SEK451.97 m SEK
EBIT409.00 m SEK412.00 m SEK
Net income351.00 m SEK332.00 m SEK
Diluted EPS – continuing operations3.48 SEK3.29 SEK

Full history since 2002, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Biogaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.